SlideShare a Scribd company logo
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
Update on COVID19 (SARS-CoV-2)
Dr.B. Clotet
Infectious Diseases Service
Hospital “Germans Trias i
Pujol. Badalona. Barcelona
(Spain)
E-mail address:
bclotet@irsicaixa.es
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
Seven Human Coronaviruses (HCoVs)
▪ Common HCoVs (lower pathogenicity):
– HCoV-229E (alpha)
– HCoV-NL63 (alpha)
– HCoV-OC43 (beta)
– HCoV-HKU1 (beta)
▪ XXI Century HCoVs (higher pathogenicity):
– SARS-CoV (beta)
– MERS-CoV (beta)
– SARS-CoV-2* (beta)
The illness COVID-19 is caused by SARS-CoV-2, which is more like SARS
CoV (79% genetic similarity) thanMERS-Co. Among all known coronavirus
sequences SARS-CoV-2 is most similar to bat coronavirus RaTG13, with
98% similarity and coronavirus sequences in the pangolín also share high
similarity. (Tay MZ et al. Nature Reviews 20;363-374:2020)
https://www.who.int/emergencies/diseases/novel‐coronavirus‐2019/technical‐guidancenaming‐the‐coronavirus‐disease‐(covid‐2019)‐and‐the‐virus‐that‐causes‐it
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
SARS-CoV & MERS-CoV Emergence in XXI Century
www.who.int access on 2020 Jan 21st
China
R0 ≈1.8-2.5
Middle
East
R0 ≈0.3-1.3
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
A seafood market in Wuhan, China the probably
source of an outbreak of a novel Coronavirus
(COVID-19) in Dec. 2019
Normile D. Science. Jan. 3, 2020; Deslandes A et al. IJAA. 2020. doi: https://doi.org/10.1016/j.ijantimicag.2020.106006
SARS-COV-2 was already
spreading in France in late
December 2019
and in Barcelona in
samples stored of residual
water was identified in
March 2019
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
Widespread rapid dissemination in our hyper-connected
world creates real-time challenges to prediction analyses
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
Incubation period 5 days (range 2-14 days)
We estimated that fewer than 2.5% of infected personswill display
symptoms within 2.2 days (CI, 1.8 to 2.9 days) o exposure, whereas
symptom onset will occur within 11.5 days (CI, 8.2 to 15.6 days)
for 97.5% of infectedpersons
Lauer SA et al. Ann Intern Med. 2020.doi:10.7326/M20-0504.
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
Spike mutation (D614G) reveals the
emergence of a more transmissible form of
SARS-CoV-2
Phylogenetic Trees based on 4,535 trimmed full genome SARS C0V02
alignments from Global Initiative for Sharing All Influenza Data (GISAID) .
Korber B et al. bioRxiv preprint doi: https://doi.org/10.1101/2020.04.29.069054. This version posted May 5, 2020
• Todate we have identified 13 mutations in Spike
that are accumulating.
• The mutation Spike D614G is of urgent concern; it
began spreading in Europe in early February, and
when introduced to new regions it rapidly becomes the
dominant form.
• With the mutation, the tripod breaks much less
frequently, meaning more of its spikes are fully
functional.
• Encouragingly, immune factors from the serum of infected people
work equally well against engineered viruses both with and without
the D614G mutation. That’s a hopeful sign that vaccine candidates in
development will work against variants with or without that mutation
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
SARS-CoV-2 Pathogenesis: ACE2 receptor & TMPRSS2 are
primarily expressed in bronchial transient secretory cells
Transient secretory cells display a transient cell state between goblet and ciliated cells in HBECs
Lukassen S et al. The EMBO Journal; 2020: e105114
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
• Virus shedding is Highest Early in the Course of Disease
• Virus shedding can occur several days prior to symptom onset (pre-
symptomatic period)
• Virus can be isolated from stool but there is no epidemiologic
evidence of fecal-oral transmission
• Virus shedding usually lasts for 10-14 days in mild/moderate cases,
and for more than 4 weeks in severe and critical cases
• Patients who recover can be PCR positive after symptoms resolve
Zou et al., N Engl J Med, 2020; Wang W et al. JAMA 2020; Aylward B et al, WHO-China Mission, 2020
Virology of SARS-CoV-2
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
Viral Shedding Greatest At Time Symptoms Start
▪ SARS-CoV-2 viral loads in 17 symptomatic patients
▪ No data regarding duration of replication-competent virus shedding (e.g., culture)
Zou et al., N Engl J Med, 2020; DOI: 0.1056/NEJMc2001737
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
SARS.CoV-2 specific CD8 and CD4 T cells
identified in 70% and 100% Covid 19
convalescent patients, respectively.
CD4 T cell responses to Spike were robust
and correlated with the magnitude of
anti-SARS-CoV-2 IgG and IgA titers.
CD8 T cells recognized Spike and M with
at least 8 SARS-CoV-2 ORFs targeted
SARS-CoV-2 reactive CD4 T cells in 40-60%
of unexposed individuals, suggesting
cross-reactive T cell recognition between
circulating “common cold” coronaviruses
and SARS-CoV-2
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
Signs/Symptoms of COVID-19
▪ The majority set of signs or symptoms can not reliably discriminate SARS-CoV-2 from
other respiratory viral illnesses such as influenza
– Subacute to acute onset
– Fever > 37,5ºC
– Non-productive cough
– Fatigue
– Headache
– Muscular and articular pain
– Dispnea
– Olfactory and taste disorders precede the onset of symptoms in 1/3 of patients*. Might be long-lasting (>>6 weeks)
– Chills, repeated shaking with chills, muscle pain, headache and sorethroat
– Diarrhoea (some reports of diarrhea alone preceding cough and fever)
– Cutaneous lesions in 20% (skin rashes-rash and hives, purple toe lesions due to vasculitis)
▪ Complications include pneumonia, respiratory failure, multiorgan system failure, thromboembolic events (Pulmonary
embolism & Stroke), myocardial infactation, myocarditis, arrhytmias, hepatitis, acute kidney injury
▪ Most people will recover spontaneously with supportive care
▪ Children tend to have milder disease than adults (unusual cases of Kawasaki disease).
Liu Chinese Med J; 2020; Wang, JAMA; 2020;. Guan N Engl J Med; 2020. Chen 2020,
Lancet; 2020; *Giacomelli A et al. Clin Infect Dis,2020.
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
Extrapulmonary Complications of COVID-19
Madjid M et al. JAMA Cardiol, March 27, 2020; Mao L et al. JAMA Neurol. April 10, 2020; Toscano G et al. NEJM, April 17, 2020; Fan Z et al. Clin Gastroenterol Hepatol. April 3 2020; Cheng Y et al. Kidney
Intern. March 20 2020; Lala A et al. medRxiv preprint doi: https://doi.org/10.1101/2020.04.20.20072702; Galvan-Casas C et al. Br J Dermatol. Apr 29 2020.
• Cardiovascular
• Neurological
• Digestive
• Others
Myocarditis and myocardial injury
Myocardial Infarction
Heart Failure Arrhythmias
Thromboembolic Disease
Stroke
Guillain–Barré Syndrome
Hepatitis
Acute kidney injury; Skin manifestations
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
Skin Manifestations in Patients Hospitalized with COVID-19
• Nationwide case collection survey of images and clinical data from 429 cases
• Clinical patterns
- Acral areas of erythema with vesicles or pustules (pseudo-chilblain)(19%)
- Other vesicular eruptions (9%)
- Urticarial lesions (19%)
- Maculopapular eruptions (47%)
- Livedo or necrosis (6%).
• Timing
- Vesicular eruptions appear early in the course of the disease (15% before other symptoms)
- The pseudo-chilblain pattern frequently appears late in the evolution of the COVID-1
disease (59% after other symptoms)
- The rest tend to appear with other symptoms of COVID-19.
Galvan-Casas C et al. Br J Dermatol. Apr 29 2020. doi: 10.1111/bjd.19163.
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
Skin Manifestations in Patients Hospitalized with COVID-19
Galvan-Casas C et al. Br J Dermatol. Apr 29 2020. doi: 10.1111/bjd.19163.
Urticarial lesions
Livedoid areas
Monomorphic disseminated vesicles
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
Chest X-ray and CT findings in SARS-CoV-2
Guang W et al. NEJM 2020; DOI: 10.1056/NEJMoa2002032
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
Chest X-ray and CT findings in SARS-CoV-2
March 4th 2020 March 7th 2020
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
In-hospital Mortality Prognostic factors
Age (per yr.): 1.10 (1.03-1.17)
SOFA score: 5.65 (2,61-12,23)
D-dimer >1 µg/mL: 18.42 (2.64-128)
Zhou F et al. Lancet, March 9, 2020https://doi.org/10.1016/
Temporal changes in laboratory markers from
illness onset in hospitalizedpatients
D-dimer Lymphocyte
IL-6 Ferritin
LDHhsTroponin
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
In-hospital Mortality Prognostic factors
Clinical variables
Williamson E et al. medRxiv preprint May 7, 2020. doi:https://doi.org/10.1101/2020.05.06.20092999.
- Age (above 50 yr.)
- Comorbidities including Obesity
Laboratory variables
- Neutrophils/Lymphocytes ratio
- IL-6, CRP, LDH, Ferritin
- D-dimer
- NT-proBNP; us-Troponin
- Degree of respiratory insufficiency
- SPO2 ≤93% (ambient air)
- PaO2/FiO2 <300 mmHg
Chest-X ray / CT scan
- Bilateral involvement
- Radiological progression (>50%)
Evolutive variables
- SOFA score
- ICU admission
- Mechanical ventilation
CALL score*
- NPV (≤6 p): 99%
- PPV (≥9 p): 78%
Pericas JM & Hernandez-Meneses M et al. Eur Heart J. 2020, in press; * Ji D et al. Clin Infect Dis. 2020
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
El estudio identificó una mayor frecuencia de 26
variantes genéticas en los pacientes afectados por
insuficiencia respiratoria, en comparación con el grupo
control no infectado, y dos de ellas, en particular
localizadas en los cromosomas 3 y 9 “mostraron una
potente asociación con la gravedad”.
Los datos mostraron que “tener el grupo sanguíneo A
se asocia con un 50% más de riesgo de necesidad
de apoyo respiratorio en caso de infección por el
coronavirus. Por el contrario, poseer el grupo
sanguíneo O confiere un efecto protector frente al
desarrollo de insuficiencia respiratoria (35% menos
de riesgo)”.
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
Ware LB et al. NEJM, 2000. Tse GMK et al. J Clin Pathol 2004; Shi Y et al. Cell Death & Differentiation. 2020.
SARS-CoV-2 (COVID19) Pathogenesis: ARDS
ACE2
0
Acute Respiratory Distress Sydrome (ARDS) pathology
Acute diffuse alveolar damage, with pulmonary edema and
formation of a hyaline membrane in a SARS-CoVpatient
The airspaces are indicated by asterisks and some of the hyaline membranes lining the
alveolar spaces are highlighted by arrows (hematoxylin and eosin stain; original
magnification,x100).
Cytokine
Storm
→ ARDS
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
Objectives COVID-19 Treatment: Treat Early & Hard
Siddiqu HK, Mehra MR. J Heart Lung Transplant. March 25th 2020 doi:10.1016/j.healun.2020.03.012
1.- Antivirals
2.- Anti-inflammatory drugs
Remdesivir, Baricitinib, Aplidina?
IL-6/IL-1/JAK inhibitors
High dose Igs
Hiperimmune serum
Monoclonal Abs
Dexametasone
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
Vaccine development
Vaccine-mediated disease enhancement (VMDE) syndrome occurred in the 1960s
with inactivated RSV and measles vaccines. VMDE results in increased disease
severity if the subject is later infected by the natural virus.
Pathogenesis of RSV VMDE is distinct from antibody disease enhancement (ADE)
which occurs for macrophage tropic viruses (Dengue in humans and feline infectious
peritonitis in cats) and is directly caused by non-neutralizing or sub neutralizing Abs
leading to more efficient viral uptake via Fcy receptor binding.
VMDE and ADE has been demonstrated for some SARS-CoV-1 vaccine candidates
in the animal models.
Preserve neutralization sensitive epitopes present in protein S in their prefusion
conformation through stabilization (2 proline residues to the top of the central helix) is
very important in any vaccine design.
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
PANCORONAVIRUS VACCINES
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
Take-home Messages
SARS-CoV-2 is a new coronavirus with high infectivity (R0=3). Cause severe
respiratory infection in 20% of cases, mainly in elderly and in patients with
comorbidities. Overall mortality is high, ≈10%.
Antiviral and anti-inflammatory drugs must be started early in order to avoid the
development of ARDS and mechanical ventilation, with 50% mortality.
 Antiviral activity of HCQ, lopinavir/ritonavir is very poor. Remdesivir is the first
antiviral that has shown clinical benefit in severe COVID-19 pneumonia and has
recently been approved by the FDA.
 IL-1 and IL-6 inhibitors are showing promising results in observational studies,
but clinical trials to demonstrate their efficacy are lacking
Case isolation, contact tracing and personal and population prevention
measures should contain the epidemic. Vaccine studies are already started.
La crisis sanitaria por la infección y la
necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
Acknowledgements
Dr JMa Miró
Dra Nuria Izquierdo
Dr Julià Blanco
Dr Jorge Carrillo
Dr Roger Paredes
To all my front-line colleagues
To our patients

More Related Content

What's hot

Covid-19 Diagnosis and Mx
Covid-19 Diagnosis and MxCovid-19 Diagnosis and Mx
Covid-19 Diagnosis and Mx
Mustafa Diaa
 
Corona virus
Corona virusCorona virus
Corona virus
Sansar Babu Tiwari
 
2019 Novel Coronavirus
2019 Novel Coronavirus2019 Novel Coronavirus
2019 Novel Coronavirus
DJ CrissCross
 
Covid 19
Covid 19Covid 19
Covid 19
Ayman Allam
 
Facts about covid_19
Facts about covid_19Facts about covid_19
Facts about covid_19
Dr Ndayisaba Corneille
 
Covid
CovidCovid
MIDDLE EAST RESPIRATORY SYNDROME CORONA VIRUS (MERS CoV)
MIDDLE EAST RESPIRATORY SYNDROME CORONA VIRUS (MERS CoV)MIDDLE EAST RESPIRATORY SYNDROME CORONA VIRUS (MERS CoV)
MIDDLE EAST RESPIRATORY SYNDROME CORONA VIRUS (MERS CoV)
Dhruvendra Pandey
 
Clinical and epidemiological features of Children with COVID 19
Clinical and epidemiological features of Children with COVID 19Clinical and epidemiological features of Children with COVID 19
Clinical and epidemiological features of Children with COVID 19
Ramin Nazari M.D
 
Kawasaki disease
Kawasaki diseaseKawasaki disease
Kawasaki disease
Ahmed Ahmed
 
COVID-19: CAUSES, SYMPTOMS AND BASIC PREVENTIVE MEASURES
COVID-19: CAUSES, SYMPTOMS AND BASIC PREVENTIVE MEASURESCOVID-19: CAUSES, SYMPTOMS AND BASIC PREVENTIVE MEASURES
COVID-19: CAUSES, SYMPTOMS AND BASIC PREVENTIVE MEASURES
DrShiv Shankar
 
Diagnosis and treatment recommendations for 2019 novel coronavirus - Dr Vigya...
Diagnosis and treatment recommendations for 2019 novel coronavirus - Dr Vigya...Diagnosis and treatment recommendations for 2019 novel coronavirus - Dr Vigya...
Diagnosis and treatment recommendations for 2019 novel coronavirus - Dr Vigya...
vigyanmishra1
 
PATHOLOGY OF COVID-19
PATHOLOGY OF COVID-19PATHOLOGY OF COVID-19
PATHOLOGY OF COVID-19
DrRashmiBudha
 
Covid 19
Covid 19Covid 19
Covid 19
Utkarsh Sharma
 
COVID 19
COVID 19  COVID 19
COVID 19
Gamal Agmy
 
Covid 19 lecture for under graduate students
Covid 19 lecture for under graduate students Covid 19 lecture for under graduate students
Covid 19 lecture for under graduate students
Dr.Farhana Yasmin
 
Novel coronavirus 2019 china nCoV2019
Novel coronavirus 2019 china nCoV2019Novel coronavirus 2019 china nCoV2019
Novel coronavirus 2019 china nCoV2019
Dr.Aslam calicut
 
Etiology and pathogenesis of covid 19
Etiology and pathogenesis of covid 19Etiology and pathogenesis of covid 19
Etiology and pathogenesis of covid 19
dharmesh chaturvedi
 
Covid 19 (corona virus)
Covid 19 (corona virus)Covid 19 (corona virus)
Covid 19 (corona virus)
Amar joseph
 
Coronaviruses & COVID 19 - Its Morphology, Role, Mechanism of Action, and Tre...
Coronaviruses & COVID 19 - Its Morphology, Role, Mechanism of Action, and Tre...Coronaviruses & COVID 19 - Its Morphology, Role, Mechanism of Action, and Tre...
Coronaviruses & COVID 19 - Its Morphology, Role, Mechanism of Action, and Tre...
Haider Ali Malik
 
Diarrea aguda infecciosa bacteriana
Diarrea aguda infecciosa bacterianaDiarrea aguda infecciosa bacteriana
Diarrea aguda infecciosa bacteriana
franklinaranda
 

What's hot (20)

Covid-19 Diagnosis and Mx
Covid-19 Diagnosis and MxCovid-19 Diagnosis and Mx
Covid-19 Diagnosis and Mx
 
Corona virus
Corona virusCorona virus
Corona virus
 
2019 Novel Coronavirus
2019 Novel Coronavirus2019 Novel Coronavirus
2019 Novel Coronavirus
 
Covid 19
Covid 19Covid 19
Covid 19
 
Facts about covid_19
Facts about covid_19Facts about covid_19
Facts about covid_19
 
Covid
CovidCovid
Covid
 
MIDDLE EAST RESPIRATORY SYNDROME CORONA VIRUS (MERS CoV)
MIDDLE EAST RESPIRATORY SYNDROME CORONA VIRUS (MERS CoV)MIDDLE EAST RESPIRATORY SYNDROME CORONA VIRUS (MERS CoV)
MIDDLE EAST RESPIRATORY SYNDROME CORONA VIRUS (MERS CoV)
 
Clinical and epidemiological features of Children with COVID 19
Clinical and epidemiological features of Children with COVID 19Clinical and epidemiological features of Children with COVID 19
Clinical and epidemiological features of Children with COVID 19
 
Kawasaki disease
Kawasaki diseaseKawasaki disease
Kawasaki disease
 
COVID-19: CAUSES, SYMPTOMS AND BASIC PREVENTIVE MEASURES
COVID-19: CAUSES, SYMPTOMS AND BASIC PREVENTIVE MEASURESCOVID-19: CAUSES, SYMPTOMS AND BASIC PREVENTIVE MEASURES
COVID-19: CAUSES, SYMPTOMS AND BASIC PREVENTIVE MEASURES
 
Diagnosis and treatment recommendations for 2019 novel coronavirus - Dr Vigya...
Diagnosis and treatment recommendations for 2019 novel coronavirus - Dr Vigya...Diagnosis and treatment recommendations for 2019 novel coronavirus - Dr Vigya...
Diagnosis and treatment recommendations for 2019 novel coronavirus - Dr Vigya...
 
PATHOLOGY OF COVID-19
PATHOLOGY OF COVID-19PATHOLOGY OF COVID-19
PATHOLOGY OF COVID-19
 
Covid 19
Covid 19Covid 19
Covid 19
 
COVID 19
COVID 19  COVID 19
COVID 19
 
Covid 19 lecture for under graduate students
Covid 19 lecture for under graduate students Covid 19 lecture for under graduate students
Covid 19 lecture for under graduate students
 
Novel coronavirus 2019 china nCoV2019
Novel coronavirus 2019 china nCoV2019Novel coronavirus 2019 china nCoV2019
Novel coronavirus 2019 china nCoV2019
 
Etiology and pathogenesis of covid 19
Etiology and pathogenesis of covid 19Etiology and pathogenesis of covid 19
Etiology and pathogenesis of covid 19
 
Covid 19 (corona virus)
Covid 19 (corona virus)Covid 19 (corona virus)
Covid 19 (corona virus)
 
Coronaviruses & COVID 19 - Its Morphology, Role, Mechanism of Action, and Tre...
Coronaviruses & COVID 19 - Its Morphology, Role, Mechanism of Action, and Tre...Coronaviruses & COVID 19 - Its Morphology, Role, Mechanism of Action, and Tre...
Coronaviruses & COVID 19 - Its Morphology, Role, Mechanism of Action, and Tre...
 
Diarrea aguda infecciosa bacteriana
Diarrea aguda infecciosa bacterianaDiarrea aguda infecciosa bacteriana
Diarrea aguda infecciosa bacteriana
 

Similar to La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario

Covid 19 - Presentation & Diagnosis
Covid 19 - Presentation & DiagnosisCovid 19 - Presentation & Diagnosis
Covid 19 - Presentation & Diagnosis
Tahseen Siddiqui
 
10 juli 21.MRCCC.Coronavirus Disease 2019 (COVID-19).pptx
10 juli 21.MRCCC.Coronavirus  Disease 2019 (COVID-19).pptx10 juli 21.MRCCC.Coronavirus  Disease 2019 (COVID-19).pptx
10 juli 21.MRCCC.Coronavirus Disease 2019 (COVID-19).pptx
EdselFGO
 
Covid19 emerging data and guidance
Covid19 emerging data and guidanceCovid19 emerging data and guidance
Covid19 emerging data and guidance
Ahmed Al Montasir
 
Covid 19--EMERGING AND FUTURE CHALLENGES FOR DENTAL SURGEON
Covid 19--EMERGING AND FUTURE CHALLENGES FOR DENTAL SURGEONCovid 19--EMERGING AND FUTURE CHALLENGES FOR DENTAL SURGEON
Covid 19--EMERGING AND FUTURE CHALLENGES FOR DENTAL SURGEON
SOUMENDU KARAK
 
Expert Eye - The Deadly Virus & The Italian Experience
Expert Eye - The Deadly Virus & The Italian ExperienceExpert Eye - The Deadly Virus & The Italian Experience
Expert Eye - The Deadly Virus & The Italian Experience
Anthony Permal
 
Gastrointestinal Manifestations of Covid 19 piyush
Gastrointestinal Manifestations of  Covid 19 piyushGastrointestinal Manifestations of  Covid 19 piyush
Gastrointestinal Manifestations of Covid 19 piyush
piyushpatwa
 
Coronavirus disease-2019-covid-19 (1)
Coronavirus disease-2019-covid-19  (1) Coronavirus disease-2019-covid-19  (1)
Coronavirus disease-2019-covid-19 (1)
Khalid Roz
 
Coronavirus disease-2019-covid-19 (1)
Coronavirus disease-2019-covid-19  (1) Coronavirus disease-2019-covid-19  (1)
Coronavirus disease-2019-covid-19 (1)
Khalid Roz
 
Coronavirus disease-2019-covid-19 (1) (1)
Coronavirus disease-2019-covid-19  (1) (1)Coronavirus disease-2019-covid-19  (1) (1)
Coronavirus disease-2019-covid-19 (1) (1)
Khalid Roz
 
CARE OF PATIENT WITH COVID-19
CARE OF PATIENT WITH COVID-19CARE OF PATIENT WITH COVID-19
Covid-19: state of art at 30.03.2020
Covid-19: state of art at 30.03.2020Covid-19: state of art at 30.03.2020
Covid-19: state of art at 30.03.2020
Valentina Corona
 
COVID VACCINE-2.pptx
COVID VACCINE-2.pptxCOVID VACCINE-2.pptx
COVID VACCINE-2.pptx
RafiqKhanani1
 
Covid19 corona virus
Covid19 corona virusCovid19 corona virus
Covid19 corona virus
Sesha Sai
 
Covid 19 diagnosis - current updates final
Covid   19 diagnosis - current  updates finalCovid   19 diagnosis - current  updates final
Covid 19 diagnosis - current updates final
Dr. Gurbilas P. Singh
 
Covid Brazilian Recomendations AMB 2021
Covid Brazilian Recomendations AMB 2021Covid Brazilian Recomendations AMB 2021
Covid Brazilian Recomendations AMB 2021
Alexandre Naime Barbosa
 
Covid 19
Covid 19Covid 19
Covid 19
Raj Mandavia
 
Med j club mm covid20
Med j  club mm covid20Med j  club mm covid20
Med j club mm covid20
Shaikhani.
 
Covid 19
Covid 19 Covid 19
Covid 19
Waheed Shouman
 
Corona update 6 CORONA INDIA IN JULY
Corona update 6 CORONA INDIA IN JULYCorona update 6 CORONA INDIA IN JULY
Corona update 6 CORONA INDIA IN JULY
NARENDRA C MALHOTRA
 
Neurologic Manifestation.pdf
Neurologic Manifestation.pdfNeurologic Manifestation.pdf
Neurologic Manifestation.pdf
WahidaPutri1
 

Similar to La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario (20)

Covid 19 - Presentation & Diagnosis
Covid 19 - Presentation & DiagnosisCovid 19 - Presentation & Diagnosis
Covid 19 - Presentation & Diagnosis
 
10 juli 21.MRCCC.Coronavirus Disease 2019 (COVID-19).pptx
10 juli 21.MRCCC.Coronavirus  Disease 2019 (COVID-19).pptx10 juli 21.MRCCC.Coronavirus  Disease 2019 (COVID-19).pptx
10 juli 21.MRCCC.Coronavirus Disease 2019 (COVID-19).pptx
 
Covid19 emerging data and guidance
Covid19 emerging data and guidanceCovid19 emerging data and guidance
Covid19 emerging data and guidance
 
Covid 19--EMERGING AND FUTURE CHALLENGES FOR DENTAL SURGEON
Covid 19--EMERGING AND FUTURE CHALLENGES FOR DENTAL SURGEONCovid 19--EMERGING AND FUTURE CHALLENGES FOR DENTAL SURGEON
Covid 19--EMERGING AND FUTURE CHALLENGES FOR DENTAL SURGEON
 
Expert Eye - The Deadly Virus & The Italian Experience
Expert Eye - The Deadly Virus & The Italian ExperienceExpert Eye - The Deadly Virus & The Italian Experience
Expert Eye - The Deadly Virus & The Italian Experience
 
Gastrointestinal Manifestations of Covid 19 piyush
Gastrointestinal Manifestations of  Covid 19 piyushGastrointestinal Manifestations of  Covid 19 piyush
Gastrointestinal Manifestations of Covid 19 piyush
 
Coronavirus disease-2019-covid-19 (1)
Coronavirus disease-2019-covid-19  (1) Coronavirus disease-2019-covid-19  (1)
Coronavirus disease-2019-covid-19 (1)
 
Coronavirus disease-2019-covid-19 (1)
Coronavirus disease-2019-covid-19  (1) Coronavirus disease-2019-covid-19  (1)
Coronavirus disease-2019-covid-19 (1)
 
Coronavirus disease-2019-covid-19 (1) (1)
Coronavirus disease-2019-covid-19  (1) (1)Coronavirus disease-2019-covid-19  (1) (1)
Coronavirus disease-2019-covid-19 (1) (1)
 
CARE OF PATIENT WITH COVID-19
CARE OF PATIENT WITH COVID-19CARE OF PATIENT WITH COVID-19
CARE OF PATIENT WITH COVID-19
 
Covid-19: state of art at 30.03.2020
Covid-19: state of art at 30.03.2020Covid-19: state of art at 30.03.2020
Covid-19: state of art at 30.03.2020
 
COVID VACCINE-2.pptx
COVID VACCINE-2.pptxCOVID VACCINE-2.pptx
COVID VACCINE-2.pptx
 
Covid19 corona virus
Covid19 corona virusCovid19 corona virus
Covid19 corona virus
 
Covid 19 diagnosis - current updates final
Covid   19 diagnosis - current  updates finalCovid   19 diagnosis - current  updates final
Covid 19 diagnosis - current updates final
 
Covid Brazilian Recomendations AMB 2021
Covid Brazilian Recomendations AMB 2021Covid Brazilian Recomendations AMB 2021
Covid Brazilian Recomendations AMB 2021
 
Covid 19
Covid 19Covid 19
Covid 19
 
Med j club mm covid20
Med j  club mm covid20Med j  club mm covid20
Med j club mm covid20
 
Covid 19
Covid 19 Covid 19
Covid 19
 
Corona update 6 CORONA INDIA IN JULY
Corona update 6 CORONA INDIA IN JULYCorona update 6 CORONA INDIA IN JULY
Corona update 6 CORONA INDIA IN JULY
 
Neurologic Manifestation.pdf
Neurologic Manifestation.pdfNeurologic Manifestation.pdf
Neurologic Manifestation.pdf
 

More from Sociedad Española de Cardiología

Hazte socio de la Sociedad Española de Cardiología
Hazte socio de la Sociedad Española de CardiologíaHazte socio de la Sociedad Española de Cardiología
Hazte socio de la Sociedad Española de Cardiología
Sociedad Española de Cardiología
 
Identificación del paciente con alto riesgo tras SCA reciente
Identificación del paciente con alto riesgo tras SCA recienteIdentificación del paciente con alto riesgo tras SCA reciente
Identificación del paciente con alto riesgo tras SCA reciente
Sociedad Española de Cardiología
 
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Sociedad Española de Cardiología
 
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Sociedad Española de Cardiología
 
Proyecto FARO. Prevención secundaria de la enfermedad cardiovascular ateroscl...
Proyecto FARO. Prevención secundaria de la enfermedad cardiovascular ateroscl...Proyecto FARO. Prevención secundaria de la enfermedad cardiovascular ateroscl...
Proyecto FARO. Prevención secundaria de la enfermedad cardiovascular ateroscl...
Sociedad Española de Cardiología
 
Estudio IVUS-ACS
Estudio IVUS-ACSEstudio IVUS-ACS
Estudio PREVENT
Estudio PREVENTEstudio PREVENT
Estudio DEDICATE-DZHK6
Estudio DEDICATE-DZHK6Estudio DEDICATE-DZHK6
Estudio DEDICATE-DZHK6
Sociedad Española de Cardiología
 
Estudio TRAVERSE
Estudio TRAVERSEEstudio TRAVERSE
Estudio FULL-REVASC
Estudio FULL-REVASCEstudio FULL-REVASC
Estudio IMPROVE-HCM
Estudio IMPROVE-HCMEstudio IMPROVE-HCM
Estudio ORBITA-COSMIC
Estudio ORBITA-COSMICEstudio ORBITA-COSMIC
Estudio ORBITA-COSMIC
Sociedad Española de Cardiología
 
Estudio ARISE-HF
Estudio ARISE-HFEstudio ARISE-HF
Estudio TACTiC
Estudio TACTiCEstudio TACTiC
Estudio ULTIMATE DAPT
Estudio ULTIMATE DAPTEstudio ULTIMATE DAPT
Estudio ULTIMATE DAPT
Sociedad Española de Cardiología
 
Estudio SHASTA-2
Estudio SHASTA-2Estudio SHASTA-2
Estudio MINT
Estudio MINTEstudio MINT
ePóster. Reducciones c-LDL el primer año de tratamiento con inclisirán
ePóster. Reducciones c-LDL el primer año de tratamiento con inclisiránePóster. Reducciones c-LDL el primer año de tratamiento con inclisirán
ePóster. Reducciones c-LDL el primer año de tratamiento con inclisirán
Sociedad Española de Cardiología
 
Estudio SMART
Estudio SMARTEstudio SMART
Estudio REDUCE-AMI
Estudio REDUCE-AMIEstudio REDUCE-AMI

More from Sociedad Española de Cardiología (20)

Hazte socio de la Sociedad Española de Cardiología
Hazte socio de la Sociedad Española de CardiologíaHazte socio de la Sociedad Española de Cardiología
Hazte socio de la Sociedad Española de Cardiología
 
Identificación del paciente con alto riesgo tras SCA reciente
Identificación del paciente con alto riesgo tras SCA recienteIdentificación del paciente con alto riesgo tras SCA reciente
Identificación del paciente con alto riesgo tras SCA reciente
 
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
 
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
 
Proyecto FARO. Prevención secundaria de la enfermedad cardiovascular ateroscl...
Proyecto FARO. Prevención secundaria de la enfermedad cardiovascular ateroscl...Proyecto FARO. Prevención secundaria de la enfermedad cardiovascular ateroscl...
Proyecto FARO. Prevención secundaria de la enfermedad cardiovascular ateroscl...
 
Estudio IVUS-ACS
Estudio IVUS-ACSEstudio IVUS-ACS
Estudio IVUS-ACS
 
Estudio PREVENT
Estudio PREVENTEstudio PREVENT
Estudio PREVENT
 
Estudio DEDICATE-DZHK6
Estudio DEDICATE-DZHK6Estudio DEDICATE-DZHK6
Estudio DEDICATE-DZHK6
 
Estudio TRAVERSE
Estudio TRAVERSEEstudio TRAVERSE
Estudio TRAVERSE
 
Estudio FULL-REVASC
Estudio FULL-REVASCEstudio FULL-REVASC
Estudio FULL-REVASC
 
Estudio IMPROVE-HCM
Estudio IMPROVE-HCMEstudio IMPROVE-HCM
Estudio IMPROVE-HCM
 
Estudio ORBITA-COSMIC
Estudio ORBITA-COSMICEstudio ORBITA-COSMIC
Estudio ORBITA-COSMIC
 
Estudio ARISE-HF
Estudio ARISE-HFEstudio ARISE-HF
Estudio ARISE-HF
 
Estudio TACTiC
Estudio TACTiCEstudio TACTiC
Estudio TACTiC
 
Estudio ULTIMATE DAPT
Estudio ULTIMATE DAPTEstudio ULTIMATE DAPT
Estudio ULTIMATE DAPT
 
Estudio SHASTA-2
Estudio SHASTA-2Estudio SHASTA-2
Estudio SHASTA-2
 
Estudio MINT
Estudio MINTEstudio MINT
Estudio MINT
 
ePóster. Reducciones c-LDL el primer año de tratamiento con inclisirán
ePóster. Reducciones c-LDL el primer año de tratamiento con inclisiránePóster. Reducciones c-LDL el primer año de tratamiento con inclisirán
ePóster. Reducciones c-LDL el primer año de tratamiento con inclisirán
 
Estudio SMART
Estudio SMARTEstudio SMART
Estudio SMART
 
Estudio REDUCE-AMI
Estudio REDUCE-AMIEstudio REDUCE-AMI
Estudio REDUCE-AMI
 

Recently uploaded

UNIT 2 Principles and Concept of Mental Health Nursing
UNIT 2 Principles and Concept of Mental Health NursingUNIT 2 Principles and Concept of Mental Health Nursing
UNIT 2 Principles and Concept of Mental Health Nursing
Prof. (Dr.) Rahul Sharma
 
Hemodialysis: Chapter 11, Venous Catheter - Basics, Insertion, Use and Care -...
Hemodialysis: Chapter 11, Venous Catheter - Basics, Insertion, Use and Care -...Hemodialysis: Chapter 11, Venous Catheter - Basics, Insertion, Use and Care -...
Hemodialysis: Chapter 11, Venous Catheter - Basics, Insertion, Use and Care -...
NephroTube - Dr.Gawad
 
OBSTETRICS SEPSIS - BUNDLE APPROACH.pptx
OBSTETRICS SEPSIS - BUNDLE APPROACH.pptxOBSTETRICS SEPSIS - BUNDLE APPROACH.pptx
OBSTETRICS SEPSIS - BUNDLE APPROACH.pptx
Niranjan Chavan
 
TEST BANK Physical Examination and Health Assessment 9th Edition by Carolyn J...
TEST BANK Physical Examination and Health Assessment 9th Edition by Carolyn J...TEST BANK Physical Examination and Health Assessment 9th Edition by Carolyn J...
TEST BANK Physical Examination and Health Assessment 9th Edition by Carolyn J...
rightmanforbloodline
 
Kayakalp Clinic Best Sexologist of patna
Kayakalp Clinic Best Sexologist of patnaKayakalp Clinic Best Sexologist of patna
Kayakalp Clinic Best Sexologist of patna
Kayakalp Clinic - Best Sexologist In Patna
 
Classification of Periodontal Diseases.pptx
Classification of Periodontal Diseases.pptxClassification of Periodontal Diseases.pptx
Classification of Periodontal Diseases.pptx
Dr Akriti Mishra
 
Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...
Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...
Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...
ailynolive
 
VIP Agra Girls Call Agra 0X0000000X Doorstep High-Profile Girl Service Call Now
VIP Agra Girls Call Agra 0X0000000X Doorstep High-Profile Girl Service Call NowVIP Agra Girls Call Agra 0X0000000X Doorstep High-Profile Girl Service Call Now
VIP Agra Girls Call Agra 0X0000000X Doorstep High-Profile Girl Service Call Now
satpalsheravatmumbai
 
Intl J Gynecology Obste - 2024 - Nwagha - Multidisciplinary approach to obs...
Intl J Gynecology   Obste - 2024 - Nwagha - Multidisciplinary approach to obs...Intl J Gynecology   Obste - 2024 - Nwagha - Multidisciplinary approach to obs...
Intl J Gynecology Obste - 2024 - Nwagha - Multidisciplinary approach to obs...
Aloy Okechukwu Ugwu
 
Introduction to Interventional Radiology.pptx
Introduction to Interventional Radiology.pptxIntroduction to Interventional Radiology.pptx
Introduction to Interventional Radiology.pptx
Dr. Dheeraj Kumar
 
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptxPICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
Aloy Okechukwu Ugwu
 
Health communication, AI and health misinformation.pptx
Health communication, AI and health misinformation.pptxHealth communication, AI and health misinformation.pptx
Health communication, AI and health misinformation.pptx
Tina Purnat
 
Hypothyroidism / Underactive thyroid gland presentation
Hypothyroidism / Underactive thyroid gland presentationHypothyroidism / Underactive thyroid gland presentation
Hypothyroidism / Underactive thyroid gland presentation
riyaramesh2003
 
Rhythm Control in Atrial Fibrillation.pdf
Rhythm Control in Atrial Fibrillation.pdfRhythm Control in Atrial Fibrillation.pdf
Rhythm Control in Atrial Fibrillation.pdf
Jim Jacob Roy
 
General Endocrinology and mechanism of action of hormones
General Endocrinology and mechanism of action of hormonesGeneral Endocrinology and mechanism of action of hormones
General Endocrinology and mechanism of action of hormones
MedicoseAcademics
 
Pernacious Anamia. payhophysiology..pptx
Pernacious Anamia. payhophysiology..pptxPernacious Anamia. payhophysiology..pptx
Pernacious Anamia. payhophysiology..pptx
Dr. vaishali Kadam
 
Ativisha by Saket in Dravyguna BAMS NCISM
Ativisha by Saket in Dravyguna BAMS NCISMAtivisha by Saket in Dravyguna BAMS NCISM
Ativisha by Saket in Dravyguna BAMS NCISM
SaketkumarSrivastava
 
rheumatoid arthritis conditions dr aseem
rheumatoid arthritis conditions dr aseemrheumatoid arthritis conditions dr aseem
rheumatoid arthritis conditions dr aseem
Dr. Aseem Goyal
 
Dr.Tarik Enaairi - Dermatology - Mastocytosis.ppsx
Dr.Tarik Enaairi - Dermatology - Mastocytosis.ppsxDr.Tarik Enaairi - Dermatology - Mastocytosis.ppsx
Dr.Tarik Enaairi - Dermatology - Mastocytosis.ppsx
Dr.Tarik Enaairi
 
CASE PRESENTATION ON CEREBROVASCULAR ACCIDENT (ACUTE ISCHEMIC STROKE) WITH HE...
CASE PRESENTATION ON CEREBROVASCULAR ACCIDENT (ACUTE ISCHEMIC STROKE) WITH HE...CASE PRESENTATION ON CEREBROVASCULAR ACCIDENT (ACUTE ISCHEMIC STROKE) WITH HE...
CASE PRESENTATION ON CEREBROVASCULAR ACCIDENT (ACUTE ISCHEMIC STROKE) WITH HE...
Bhavana
 

Recently uploaded (20)

UNIT 2 Principles and Concept of Mental Health Nursing
UNIT 2 Principles and Concept of Mental Health NursingUNIT 2 Principles and Concept of Mental Health Nursing
UNIT 2 Principles and Concept of Mental Health Nursing
 
Hemodialysis: Chapter 11, Venous Catheter - Basics, Insertion, Use and Care -...
Hemodialysis: Chapter 11, Venous Catheter - Basics, Insertion, Use and Care -...Hemodialysis: Chapter 11, Venous Catheter - Basics, Insertion, Use and Care -...
Hemodialysis: Chapter 11, Venous Catheter - Basics, Insertion, Use and Care -...
 
OBSTETRICS SEPSIS - BUNDLE APPROACH.pptx
OBSTETRICS SEPSIS - BUNDLE APPROACH.pptxOBSTETRICS SEPSIS - BUNDLE APPROACH.pptx
OBSTETRICS SEPSIS - BUNDLE APPROACH.pptx
 
TEST BANK Physical Examination and Health Assessment 9th Edition by Carolyn J...
TEST BANK Physical Examination and Health Assessment 9th Edition by Carolyn J...TEST BANK Physical Examination and Health Assessment 9th Edition by Carolyn J...
TEST BANK Physical Examination and Health Assessment 9th Edition by Carolyn J...
 
Kayakalp Clinic Best Sexologist of patna
Kayakalp Clinic Best Sexologist of patnaKayakalp Clinic Best Sexologist of patna
Kayakalp Clinic Best Sexologist of patna
 
Classification of Periodontal Diseases.pptx
Classification of Periodontal Diseases.pptxClassification of Periodontal Diseases.pptx
Classification of Periodontal Diseases.pptx
 
Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...
Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...
Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...
 
VIP Agra Girls Call Agra 0X0000000X Doorstep High-Profile Girl Service Call Now
VIP Agra Girls Call Agra 0X0000000X Doorstep High-Profile Girl Service Call NowVIP Agra Girls Call Agra 0X0000000X Doorstep High-Profile Girl Service Call Now
VIP Agra Girls Call Agra 0X0000000X Doorstep High-Profile Girl Service Call Now
 
Intl J Gynecology Obste - 2024 - Nwagha - Multidisciplinary approach to obs...
Intl J Gynecology   Obste - 2024 - Nwagha - Multidisciplinary approach to obs...Intl J Gynecology   Obste - 2024 - Nwagha - Multidisciplinary approach to obs...
Intl J Gynecology Obste - 2024 - Nwagha - Multidisciplinary approach to obs...
 
Introduction to Interventional Radiology.pptx
Introduction to Interventional Radiology.pptxIntroduction to Interventional Radiology.pptx
Introduction to Interventional Radiology.pptx
 
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptxPICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
 
Health communication, AI and health misinformation.pptx
Health communication, AI and health misinformation.pptxHealth communication, AI and health misinformation.pptx
Health communication, AI and health misinformation.pptx
 
Hypothyroidism / Underactive thyroid gland presentation
Hypothyroidism / Underactive thyroid gland presentationHypothyroidism / Underactive thyroid gland presentation
Hypothyroidism / Underactive thyroid gland presentation
 
Rhythm Control in Atrial Fibrillation.pdf
Rhythm Control in Atrial Fibrillation.pdfRhythm Control in Atrial Fibrillation.pdf
Rhythm Control in Atrial Fibrillation.pdf
 
General Endocrinology and mechanism of action of hormones
General Endocrinology and mechanism of action of hormonesGeneral Endocrinology and mechanism of action of hormones
General Endocrinology and mechanism of action of hormones
 
Pernacious Anamia. payhophysiology..pptx
Pernacious Anamia. payhophysiology..pptxPernacious Anamia. payhophysiology..pptx
Pernacious Anamia. payhophysiology..pptx
 
Ativisha by Saket in Dravyguna BAMS NCISM
Ativisha by Saket in Dravyguna BAMS NCISMAtivisha by Saket in Dravyguna BAMS NCISM
Ativisha by Saket in Dravyguna BAMS NCISM
 
rheumatoid arthritis conditions dr aseem
rheumatoid arthritis conditions dr aseemrheumatoid arthritis conditions dr aseem
rheumatoid arthritis conditions dr aseem
 
Dr.Tarik Enaairi - Dermatology - Mastocytosis.ppsx
Dr.Tarik Enaairi - Dermatology - Mastocytosis.ppsxDr.Tarik Enaairi - Dermatology - Mastocytosis.ppsx
Dr.Tarik Enaairi - Dermatology - Mastocytosis.ppsx
 
CASE PRESENTATION ON CEREBROVASCULAR ACCIDENT (ACUTE ISCHEMIC STROKE) WITH HE...
CASE PRESENTATION ON CEREBROVASCULAR ACCIDENT (ACUTE ISCHEMIC STROKE) WITH HE...CASE PRESENTATION ON CEREBROVASCULAR ACCIDENT (ACUTE ISCHEMIC STROKE) WITH HE...
CASE PRESENTATION ON CEREBROVASCULAR ACCIDENT (ACUTE ISCHEMIC STROKE) WITH HE...
 

La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario

  • 1. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala Update on COVID19 (SARS-CoV-2) Dr.B. Clotet Infectious Diseases Service Hospital “Germans Trias i Pujol. Badalona. Barcelona (Spain) E-mail address: bclotet@irsicaixa.es
  • 2. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala Seven Human Coronaviruses (HCoVs) ▪ Common HCoVs (lower pathogenicity): – HCoV-229E (alpha) – HCoV-NL63 (alpha) – HCoV-OC43 (beta) – HCoV-HKU1 (beta) ▪ XXI Century HCoVs (higher pathogenicity): – SARS-CoV (beta) – MERS-CoV (beta) – SARS-CoV-2* (beta) The illness COVID-19 is caused by SARS-CoV-2, which is more like SARS CoV (79% genetic similarity) thanMERS-Co. Among all known coronavirus sequences SARS-CoV-2 is most similar to bat coronavirus RaTG13, with 98% similarity and coronavirus sequences in the pangolín also share high similarity. (Tay MZ et al. Nature Reviews 20;363-374:2020) https://www.who.int/emergencies/diseases/novel‐coronavirus‐2019/technical‐guidancenaming‐the‐coronavirus‐disease‐(covid‐2019)‐and‐the‐virus‐that‐causes‐it
  • 3. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala SARS-CoV & MERS-CoV Emergence in XXI Century www.who.int access on 2020 Jan 21st China R0 ≈1.8-2.5 Middle East R0 ≈0.3-1.3
  • 4. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala A seafood market in Wuhan, China the probably source of an outbreak of a novel Coronavirus (COVID-19) in Dec. 2019 Normile D. Science. Jan. 3, 2020; Deslandes A et al. IJAA. 2020. doi: https://doi.org/10.1016/j.ijantimicag.2020.106006 SARS-COV-2 was already spreading in France in late December 2019 and in Barcelona in samples stored of residual water was identified in March 2019
  • 5. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala Widespread rapid dissemination in our hyper-connected world creates real-time challenges to prediction analyses
  • 6. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala Incubation period 5 days (range 2-14 days) We estimated that fewer than 2.5% of infected personswill display symptoms within 2.2 days (CI, 1.8 to 2.9 days) o exposure, whereas symptom onset will occur within 11.5 days (CI, 8.2 to 15.6 days) for 97.5% of infectedpersons Lauer SA et al. Ann Intern Med. 2020.doi:10.7326/M20-0504.
  • 7. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala Spike mutation (D614G) reveals the emergence of a more transmissible form of SARS-CoV-2 Phylogenetic Trees based on 4,535 trimmed full genome SARS C0V02 alignments from Global Initiative for Sharing All Influenza Data (GISAID) . Korber B et al. bioRxiv preprint doi: https://doi.org/10.1101/2020.04.29.069054. This version posted May 5, 2020 • Todate we have identified 13 mutations in Spike that are accumulating. • The mutation Spike D614G is of urgent concern; it began spreading in Europe in early February, and when introduced to new regions it rapidly becomes the dominant form. • With the mutation, the tripod breaks much less frequently, meaning more of its spikes are fully functional. • Encouragingly, immune factors from the serum of infected people work equally well against engineered viruses both with and without the D614G mutation. That’s a hopeful sign that vaccine candidates in development will work against variants with or without that mutation
  • 8. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala SARS-CoV-2 Pathogenesis: ACE2 receptor & TMPRSS2 are primarily expressed in bronchial transient secretory cells Transient secretory cells display a transient cell state between goblet and ciliated cells in HBECs Lukassen S et al. The EMBO Journal; 2020: e105114
  • 9. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala • Virus shedding is Highest Early in the Course of Disease • Virus shedding can occur several days prior to symptom onset (pre- symptomatic period) • Virus can be isolated from stool but there is no epidemiologic evidence of fecal-oral transmission • Virus shedding usually lasts for 10-14 days in mild/moderate cases, and for more than 4 weeks in severe and critical cases • Patients who recover can be PCR positive after symptoms resolve Zou et al., N Engl J Med, 2020; Wang W et al. JAMA 2020; Aylward B et al, WHO-China Mission, 2020 Virology of SARS-CoV-2
  • 10. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala Viral Shedding Greatest At Time Symptoms Start ▪ SARS-CoV-2 viral loads in 17 symptomatic patients ▪ No data regarding duration of replication-competent virus shedding (e.g., culture) Zou et al., N Engl J Med, 2020; DOI: 0.1056/NEJMc2001737
  • 11. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
  • 12. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala SARS.CoV-2 specific CD8 and CD4 T cells identified in 70% and 100% Covid 19 convalescent patients, respectively. CD4 T cell responses to Spike were robust and correlated with the magnitude of anti-SARS-CoV-2 IgG and IgA titers. CD8 T cells recognized Spike and M with at least 8 SARS-CoV-2 ORFs targeted SARS-CoV-2 reactive CD4 T cells in 40-60% of unexposed individuals, suggesting cross-reactive T cell recognition between circulating “common cold” coronaviruses and SARS-CoV-2
  • 13. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
  • 14. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
  • 15. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
  • 16. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
  • 17. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala Signs/Symptoms of COVID-19 ▪ The majority set of signs or symptoms can not reliably discriminate SARS-CoV-2 from other respiratory viral illnesses such as influenza – Subacute to acute onset – Fever > 37,5ºC – Non-productive cough – Fatigue – Headache – Muscular and articular pain – Dispnea – Olfactory and taste disorders precede the onset of symptoms in 1/3 of patients*. Might be long-lasting (>>6 weeks) – Chills, repeated shaking with chills, muscle pain, headache and sorethroat – Diarrhoea (some reports of diarrhea alone preceding cough and fever) – Cutaneous lesions in 20% (skin rashes-rash and hives, purple toe lesions due to vasculitis) ▪ Complications include pneumonia, respiratory failure, multiorgan system failure, thromboembolic events (Pulmonary embolism & Stroke), myocardial infactation, myocarditis, arrhytmias, hepatitis, acute kidney injury ▪ Most people will recover spontaneously with supportive care ▪ Children tend to have milder disease than adults (unusual cases of Kawasaki disease). Liu Chinese Med J; 2020; Wang, JAMA; 2020;. Guan N Engl J Med; 2020. Chen 2020, Lancet; 2020; *Giacomelli A et al. Clin Infect Dis,2020.
  • 18. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala Extrapulmonary Complications of COVID-19 Madjid M et al. JAMA Cardiol, March 27, 2020; Mao L et al. JAMA Neurol. April 10, 2020; Toscano G et al. NEJM, April 17, 2020; Fan Z et al. Clin Gastroenterol Hepatol. April 3 2020; Cheng Y et al. Kidney Intern. March 20 2020; Lala A et al. medRxiv preprint doi: https://doi.org/10.1101/2020.04.20.20072702; Galvan-Casas C et al. Br J Dermatol. Apr 29 2020. • Cardiovascular • Neurological • Digestive • Others Myocarditis and myocardial injury Myocardial Infarction Heart Failure Arrhythmias Thromboembolic Disease Stroke Guillain–Barré Syndrome Hepatitis Acute kidney injury; Skin manifestations
  • 19. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala Skin Manifestations in Patients Hospitalized with COVID-19 • Nationwide case collection survey of images and clinical data from 429 cases • Clinical patterns - Acral areas of erythema with vesicles or pustules (pseudo-chilblain)(19%) - Other vesicular eruptions (9%) - Urticarial lesions (19%) - Maculopapular eruptions (47%) - Livedo or necrosis (6%). • Timing - Vesicular eruptions appear early in the course of the disease (15% before other symptoms) - The pseudo-chilblain pattern frequently appears late in the evolution of the COVID-1 disease (59% after other symptoms) - The rest tend to appear with other symptoms of COVID-19. Galvan-Casas C et al. Br J Dermatol. Apr 29 2020. doi: 10.1111/bjd.19163.
  • 20. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala Skin Manifestations in Patients Hospitalized with COVID-19 Galvan-Casas C et al. Br J Dermatol. Apr 29 2020. doi: 10.1111/bjd.19163. Urticarial lesions Livedoid areas Monomorphic disseminated vesicles
  • 21. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala Chest X-ray and CT findings in SARS-CoV-2 Guang W et al. NEJM 2020; DOI: 10.1056/NEJMoa2002032
  • 22. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala Chest X-ray and CT findings in SARS-CoV-2 March 4th 2020 March 7th 2020
  • 23. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala In-hospital Mortality Prognostic factors Age (per yr.): 1.10 (1.03-1.17) SOFA score: 5.65 (2,61-12,23) D-dimer >1 µg/mL: 18.42 (2.64-128) Zhou F et al. Lancet, March 9, 2020https://doi.org/10.1016/ Temporal changes in laboratory markers from illness onset in hospitalizedpatients D-dimer Lymphocyte IL-6 Ferritin LDHhsTroponin
  • 24. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala In-hospital Mortality Prognostic factors Clinical variables Williamson E et al. medRxiv preprint May 7, 2020. doi:https://doi.org/10.1101/2020.05.06.20092999. - Age (above 50 yr.) - Comorbidities including Obesity Laboratory variables - Neutrophils/Lymphocytes ratio - IL-6, CRP, LDH, Ferritin - D-dimer - NT-proBNP; us-Troponin - Degree of respiratory insufficiency - SPO2 ≤93% (ambient air) - PaO2/FiO2 <300 mmHg Chest-X ray / CT scan - Bilateral involvement - Radiological progression (>50%) Evolutive variables - SOFA score - ICU admission - Mechanical ventilation CALL score* - NPV (≤6 p): 99% - PPV (≥9 p): 78% Pericas JM & Hernandez-Meneses M et al. Eur Heart J. 2020, in press; * Ji D et al. Clin Infect Dis. 2020
  • 25. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala El estudio identificó una mayor frecuencia de 26 variantes genéticas en los pacientes afectados por insuficiencia respiratoria, en comparación con el grupo control no infectado, y dos de ellas, en particular localizadas en los cromosomas 3 y 9 “mostraron una potente asociación con la gravedad”. Los datos mostraron que “tener el grupo sanguíneo A se asocia con un 50% más de riesgo de necesidad de apoyo respiratorio en caso de infección por el coronavirus. Por el contrario, poseer el grupo sanguíneo O confiere un efecto protector frente al desarrollo de insuficiencia respiratoria (35% menos de riesgo)”.
  • 26. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala Ware LB et al. NEJM, 2000. Tse GMK et al. J Clin Pathol 2004; Shi Y et al. Cell Death & Differentiation. 2020. SARS-CoV-2 (COVID19) Pathogenesis: ARDS ACE2 0 Acute Respiratory Distress Sydrome (ARDS) pathology Acute diffuse alveolar damage, with pulmonary edema and formation of a hyaline membrane in a SARS-CoVpatient The airspaces are indicated by asterisks and some of the hyaline membranes lining the alveolar spaces are highlighted by arrows (hematoxylin and eosin stain; original magnification,x100). Cytokine Storm → ARDS
  • 27. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala Objectives COVID-19 Treatment: Treat Early & Hard Siddiqu HK, Mehra MR. J Heart Lung Transplant. March 25th 2020 doi:10.1016/j.healun.2020.03.012 1.- Antivirals 2.- Anti-inflammatory drugs Remdesivir, Baricitinib, Aplidina? IL-6/IL-1/JAK inhibitors High dose Igs Hiperimmune serum Monoclonal Abs Dexametasone
  • 28. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala Vaccine development Vaccine-mediated disease enhancement (VMDE) syndrome occurred in the 1960s with inactivated RSV and measles vaccines. VMDE results in increased disease severity if the subject is later infected by the natural virus. Pathogenesis of RSV VMDE is distinct from antibody disease enhancement (ADE) which occurs for macrophage tropic viruses (Dengue in humans and feline infectious peritonitis in cats) and is directly caused by non-neutralizing or sub neutralizing Abs leading to more efficient viral uptake via Fcy receptor binding. VMDE and ADE has been demonstrated for some SARS-CoV-1 vaccine candidates in the animal models. Preserve neutralization sensitive epitopes present in protein S in their prefusion conformation through stabilization (2 proline residues to the top of the central helix) is very important in any vaccine design.
  • 29. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala
  • 30. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala PANCORONAVIRUS VACCINES
  • 31. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala Take-home Messages SARS-CoV-2 is a new coronavirus with high infectivity (R0=3). Cause severe respiratory infection in 20% of cases, mainly in elderly and in patients with comorbidities. Overall mortality is high, ≈10%. Antiviral and anti-inflammatory drugs must be started early in order to avoid the development of ARDS and mechanical ventilation, with 50% mortality.  Antiviral activity of HCQ, lopinavir/ritonavir is very poor. Remdesivir is the first antiviral that has shown clinical benefit in severe COVID-19 pneumonia and has recently been approved by the FDA.  IL-1 and IL-6 inhibitors are showing promising results in observational studies, but clinical trials to demonstrate their efficacy are lacking Case isolation, contact tracing and personal and population prevention measures should contain the epidemic. Vaccine studies are already started.
  • 32. La crisis sanitaria por la infección y la necesaria adaptación del sistema sanitario Dr. Bonaventura Clotet Sala Acknowledgements Dr JMa Miró Dra Nuria Izquierdo Dr Julià Blanco Dr Jorge Carrillo Dr Roger Paredes To all my front-line colleagues To our patients